Gastroparesis News and Research

RSS

Gastroparesis, also called delayed gastric emptying, is a disorder in which the stomach takes too long to empty its contents. Normally, the stomach contracts to move food down into the small intestine for digestion. The vagus nerve controls the movement of food from the stomach through the digestive tract. Gastroparesis occurs when the vagus nerve is damaged and the muscles of the stomach and intestines do not work normally. Food then moves slowly or stops moving through the digestive tract.

Johns Hopkins study shows that healthy adult gut loses and regenerates nerve cells

Johns Hopkins researchers today published new evidence refuting the long-held scientific belief that the gut nerve cells we're born with are the same ones we die with.

19 Apr 2017

TTUHSC El Paso investigators receive $1.8 million grant to support digestive disorder research

Co-principal investigators Richard McCallum, M.D., and Irene Sarosiek, M.D., have received a five-year, $1.8 million grant from the National Institute of Diabetes and Digestive and Kidney Diseases.

10 Nov 2016

Cairn launches non-invasive Gastric Emptying Breath Test for measuring rate of gastroparesis in adults

Cairn Diagnostics, formerly known as Advanced Breath Diagnostics (ABDiagnostics), has launched the 13C-Spirulina Gastric Emptying Breath Test (GEBT).

30 Mar 2016

Rhythm Metabolic awarded FDA grant to advance ongoing setmelanotide clinical trial in Prader-Willi syndrome

Rhythm announced today the award of a $1 million research grant from the FDA Office of Orphan Products Development to its subsidiary, Rhythm Metabolic, Inc., to support the ongoing Phase 2 clinical trial of setmelanotide, the company's novel peptide MC4 agonist, for the treatment of obesity and hyperphagia in Prader-Willi syndrome (PWS).

24 Sep 2015

Rhythm Metabolic completes $40 million Series A financing

Rhythm announced today the completion of a $40 million Series A financing for its subsidiary, Rhythm Metabolic, Inc., which is developing setmelanotide (RM-493), a novel peptide MC4 agonist for the treatment of obesity caused by genetic deficiencies in the MC4 pathway.

13 Aug 2015

Once-weekly Trulicity 0.75 mg shows promising results in Japanese patients with type 2 diabetes

Results from a new study of Japanese patients with type 2 diabetes showed once-weekly Trulicity 0.75 mg provided greater hemoglobin A1c (A1C) reduction compared to once-daily Victoza 0.9 mg after 52 weeks of treatment. Eli Lilly and Company will present these data at the 75th American Diabetes Association Scientific Sessions in Boston.

7 Jun 2015

Rhythm announces initiation of two setmelanotide Phase 2 trials for treatment of PWS, POMC-null obesity

Rhythm announced today the initiation of two Phase 2 clinical trials focused on evaluating the safety and effectiveness of setmelanotide (RM-493), the company's novel melanocortin 4 receptor (MC4R) agonist, for the treatment of Prader-Willi Syndrome (PWS) and POMC-null obesity.

4 Jun 2015

New clinical data demonstrating treatment options in Lilly's diabetes portfolio to be presented at ADA Scientific Sessions

New clinical data demonstrating the range of treatment options represented in Lilly's diabetes portfolio will be presented in 79 abstracts on June 5-9, at the 75th American Diabetes Association (ADA)® Scientific Sessions in Boston.

29 May 2015

Rhythm, Actavis announce initiation of relamorelin Phase 2b trial for treatment of diabetic gastroparesis

Rhythm, a biopharmaceutical company, and Actavis plc, a leading global pharmaceutical company, announced today the initiation of a Phase 2b clinical trial assessing the efficacy and safety of relamorelin (RM-131), Rhythm's ghrelin agonist, for the treatment of gastroparesis in patients with type 1 and type 2 diabetes.

8 Apr 2015

Actavis provides overview of standalone global pharmaceutical development pipeline

Actavis plc, during its Investor Meeting in New York, today provided a detailed look into its standalone global pharmaceutical development pipeline that supports the Company's long-term organic growth. The Company provided details regarding key development programs, including clinical data, development milestones and an overview of potential market opportunities, as well as an updated look at Actavis' world-class generics pipeline, which continues to hold an industry-leading position in First-to-File opportunities in the U.S.

18 Feb 2015

Altos Therapeutics announces issuance of Mexican patent covering dopamine D2/D3 drug candidates

Altos Therapeutics, LLC announced today that the Mexican Institute of Industrial Property has issued Patent Number 323020 titled, "D2 Antagonists, Methods of Synthesis and Methods of Use". The patent broadly and specifically covers the company's dopamine D2/D3 drug candidates, their pharmaceutical compositions, and their use to treat a number of important gastrointestinal conditions in humans, such as gastroparesis.

12 Jan 2015

GSK announces availability of once-weekly Tanzeum in pharmacies throughout the U.S.

GSK today announced that once-weekly Tanzeum (albiglutide), a prescription injectable treatment for type 2 diabetes in adults, as an adjunct to diet and exercise, is now available in pharmacies throughout the U.S.

29 Jul 2014

Targacept reports net loss of $11.6M in first quarter 2014

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today reported its financial results for the first quarter ended March 31, 2014.

7 May 2014

Antidepressant nortriptyline does not improve overall symptoms in patients with idiopathic gastroparesis

Among patients with idiopathic (of unknown cause) gastroparesis, use of the antidepressant nortriptyline compared with placebo for 15 weeks did not result in improvement in overall symptoms, according to a study appearing in the December 25 issue of JAMA.

25 Dec 2013

Targacept reports top-line results from TC-5619 Phase 2b trial for negative symptoms in schizophrenia

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced top-line results from a Phase 2b clinical trial of TC-5619 as an augmentation therapy for the treatment of negative symptoms of schizophrenia.

17 Dec 2013

Dietary modifications can reduce gastroparesis in diabetes patients

Many diabetes patients suffer from symptoms such as nausea, vomiting and lack of appetite. A doctoral thesis from the Sahlgrenska Academy shows that a diet consisting of foods that fall apart easily, for example boiled potatoes and fish gratin, can help alleviate the condition.

5 Oct 2013

Rhythm starts RM-493 clinical trials in obesity patients with genetic deficiency

Rhythm announced today the initiation of the first of a series of clinical trials with RM-493, the company's novel melanocortin 4 receptor (MC4R) agonist, for the treatment of obesity in individuals with a genetic deficiency in the MC4R pathway.

24 Sep 2013

Rhythm Awarded $1.35M From Michael J. Fox Foundation

...

10 Sep 2013

MJFF awards $1.35M to Rhythm for Phase 2 clinical trial of RM-131 for Parkinson's disease

Rhythm announced today that The Michael J. Fox Foundation for Parkinson's Research has awarded a $1.35 million research grant to Rhythm to help fund a Phase 2 clinical trial of RM-131, the company's novel ghrelin agonist, for the treatment of refractory constipation in patients with Parkinson's disease.